Malignant hyperthermia (MH) is an uncommon hereditary condition that gives rise to a potentially life-threatening reaction in the skeletal muscles known as a fulminant MH event. This pharmacogenetic disorder is primarily triggered by volatile anesthetics or polarizing skeletal muscle relaxants. Although it is extremely rare, stress, exercise, or high environmental temperatures can also act as triggers for a fulminant MH event. Immediate intervention and treatment are crucial as the fatality rate can reach up to 70% if proper action is not taken promptly. It is important to note that children face a higher risk of fatality in such cases.
Recognizing the Signs and Symptoms of Malignant Hyperthermia
Malignant hyperthermia can be identified through various signs and symptoms that manifest in affected individuals. These indicators include muscle rigidity, a significantly elevated body temperature, and a rapid heart rate. Additionally, an individual experiencing a fulminant MH event may exhibit increased acid content in their muscles and an accumulation of carbon dioxide in their bloodstream. It is important to note that the onset of a fulminant MH event can happen swiftly, occurring within a matter of minutes or hours after a patient has been administered anesthesia.
Fulminant Malignant Hyperthermia
Fulminant malignant hyperthermia can vary in its presentation from one episode to another. It is possible for an individual to undergo anesthesia successfully in previous procedures and still experience a fulminant MH event. Vigilance for MH is crucial for medical professionals at all times. The symptoms exhibited by individuals may differ, making it the responsibility of anesthesiologists and care providers assisting the surgeon to carefully monitor for any signs of MH and promptly inform the specialist. Once a person who has undergone an MH event stabilizes, the doctor will conduct a muscle biopsy for further testing.